Arecor Therapeutics PLC Arecor presents positive data for AT247 at ADA

TIDMAREC

Arecor Therapeutics PLC

26 June 2023

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

Arecor presents positive data from US phase I clinical trial of ultra-rapid acting insulin candidate AT247 delivered via insulin pump at ADA annual meeting

   -      Data presented at the American Diabetes Association 83(rd) Scientific Sessions

- AT247 delivers significantly accelerated insulin absorption and early exposure (PK profile) compared with NovoLog(R) and Fiasp(R)

- Further supports potential to enable more effective disease management for people with Type I diabetes via fully automated closed loop insulin pump delivery (artificial pancreas)

Cambridge, UK, 26 June 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that positive results from its second Phase I clinical trial investigating ultra-rapid acting insulin product candidate, AT247, have been shared in a poster presentation at the American Diabetes Association (ADA) 83(rd) Scientific Sessions meeting, being held until today in San Diego, California and online.

The poster, "Double blind cross over study of ultra-rapid AT247 compared with NovoLog(R) and Fiasp(R) during continuous subcutaneous infusion (CSII) assessed by a hyperinsulinemic euglycemic clamp", is displayed in the meeting's Poster Hall and available as an ePoster for virtual attendees.

Dr Marcus Hompesch, MD. President and Chief Executive Officer of ProSciento Inc, said: "AT247 has demonstrated faster insulin absorption when delivered by continuous infusion via an insulin pump, compared to other rapid acting insulins currently available to patients. Its PK profile offers the potential to further improve blood glucose control, and may play an important role in facilitating a fully closed loop artificial pancreas - a life changing treatment approach for people living with diabetes."

Sarah Howell, Chief Executive Officer of Arecor, added: "These data reinforce AT247's potential to enable even more effective disease management for people with Type I diabetes. The availability of a truly ultra-rapid acting insulin will be a key component in the move towards a fully closed loop artificial pancreas system, a potentially life changing treatment option for people living with diabetes, improving health outcomes and reducing the significant burden of managing this chronic disease. With AT247, Arecor has the ability to significantly advance the diabetic treatment landscape and, ultimately, deliver better health outcomes for patients."

AT247 is a 100U/mL ultra-rapid acting novel formulation of insulin that has been designed to accelerate the absorption of insulin following subcutaneous injection, to enable more effective management of blood glucose levels for people living with diabetes.

In the Phase I trial, faster absorption of AT247 resulted in higher early insulin exposure than with gold standard insulins NovoLog(R) and Fiasp(R) following bolus dose delivery during continuous subcutaneous infusion. The demonstrated PK profile of AT247 supports further investigation into its potential to further improve automated insulin delivery and builds on the superior PK/PD profile of a single AT247 dose compared with NovoLog(R) and Fiasp(R), previously demonstrated in an earlier Phase I study.

Headline results from the ARE-AT247-103 clinical trial were announced by the Company on 11 October 2022.

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                  www.arecor.com 
 Dr Sarah Howell, Chief Executive         Tel: +44 (0) 1223 426060 
  Officer                                  Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer   Tel: +44 (0) 1223 426060 
                                           Email: info@arecor.com 
 
 Mo Noonan, Communications                Tel: +44 (0) 7876 444977 
                                           Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD       Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications 
 Chris Gardner, David Daley, Angela       Tel: +44 (0) 20 3709 5700 
  Gray                                     Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABUGDLBUDDGXX

(END) Dow Jones Newswires

June 26, 2023 02:00 ET (06:00 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024